Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNS007
MIFTS: 51

Bone Sarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bone Sarcoma

About this section

MalaCards integrated aliases for Bone Sarcoma:

Name: Bone Sarcoma 12 58 15

Characteristics:

Orphanet epidemiological data:

58
bone sarcoma
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:0080639
UMLS via Orphanet 72 C0029463 C1704327
Orphanet 58 ORPHA223727
Sources

Summaries for Bone Sarcoma

About this section
Disease Ontology : 12 A bone cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Bone Sarcoma is related to spindle cell sarcoma and muscle cancer. An important gene associated with Bone Sarcoma is CCNB3 (Cyclin B3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Sirolimus and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and brain, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 A bone sarcoma is a primary malignant bone tumour, a type of sarcoma that starts in the bones. This is... more...

Sources

Related Diseases for Bone Sarcoma

About this section

Diseases related to Bone Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 459)
# Related Disease Score Top Affiliating Genes
1 spindle cell sarcoma 32.2 SERPINA3 IL6 CCNB3
2 muscle cancer 32.1 SERPINA3 MIR199A1 MB
3 neutropenia 31.1 TNFRSF1A IL6 IL1RN IL10 CXCL8 CSF3
4 malignant fibrous histiocytoma 31.0 SERPINA3 MTAP MB
5 exanthem 30.7 IL6 IL10 CXCL8 CTLA4 CSF3
6 osteomyelitis 30.7 IL6 IL1RN IL10 CXCL8 CSF3
7 stomatitis 30.6 IL6 IL10 CXCL8 CSF3
8 bone cancer 30.6 SERPINA3 MTAP MIR542 MIR199A1 KDM4C IL6
9 dedifferentiated liposarcoma 30.5 SERPINA3 MIR100 MB
10 diarrhea 30.5 IL6 IL10 CXCL8 CSF3
11 paracoccidioidomycosis 30.4 IL6 IL10 CXCL8 CTLA4
12 mesenchymal cell neoplasm 30.4 SERPINA3 MIR199A1 CCNB3
13 bone resorption disease 30.4 SERPINA3 MIR199A1 IL6 CSF1
14 toxic shock syndrome 30.3 IL6 IL1RN IL1R1 IL10 CXCL8
15 mucositis 30.3 TNFRSF1A IL10 CSF3
16 severe acute respiratory syndrome 30.3 IL6 IL10 CXCL8
17 osteoporosis 30.2 SRC IL6 IL1RN IL10 CXCL8 CSF1
18 rheumatoid arthritis 30.1 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8
19 thrombocytopenia 30.1 TNFRSF1A SRC IL6 IL1RN IL10 CXCL8
20 bone inflammation disease 30.1 TNFRSF1A SERPINA3 MIR199A1 IL6 IL1RN IL10
21 systemic lupus erythematosus 30.0 TNFRSF1A MIR195 IL6 IL1RN IL1R1 IL10
22 osteogenic sarcoma 11.4
23 chondrosarcoma 11.2
24 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.2
25 soft tissue sarcoma 11.1
26 ewing sarcoma 11.0
27 sarcoma 11.0
28 bone giant cell tumor 10.9
29 fibrosarcoma of bone 10.9
30 mesenchymal chondrosarcoma 10.9
31 clear cell chondrosarcoma 10.9
32 acute transverse myelitis 10.6 IL6 IL10 CXCL8
33 transverse myelitis 10.6 IL6 IL10 CXCL8
34 acute gonococcal cervicitis 10.6 IL6 IL10 CXCL8
35 cervicitis 10.6 IL6 IL10 CXCL8
36 bacterial conjunctivitis 10.6 IL6 IL10 CXCL8
37 conjunctivitis 10.6 IL6 IL10 CXCL8
38 idiopathic anterior uveitis 10.6 IL6 CXCL8
39 enterocolitis 10.6 IL6 IL10 CXCL8
40 progressive myoclonus epilepsy 8 10.6 IL6 IL10 CXCL8
41 vaginal discharge 10.6 IL6 IL10 CXCL8
42 periapical periodontitis 10.6 IL6 IL10 CXCL8
43 trichomoniasis 10.6 IL6 IL10 CXCL8
44 chlamydia pneumonia 10.6 IL6 IL10 CXCL8
45 chlamydia 10.6 IL6 IL10 CXCL8
46 cardiomyopathy, familial hypertrophic, 20 10.6 IL6 IL10 CXCL8
47 fungal meningitis 10.6 IL6 IL10 CXCL8
48 cryopyrin-associated periodic syndrome 10.6 IL6 IL1RN IL1R1
49 urethritis 10.6 IL6 IL10 CXCL8
50 funisitis 10.6 IL6 IL10 CXCL8

Graphical network of the top 20 diseases related to Bone Sarcoma:



Diseases related to Bone Sarcoma
Sources

Symptoms & Phenotypes for Bone Sarcoma

About this section

MGI Mouse Phenotypes related to Bone Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 BCOR CSF1 CSF3 CTLA4 IL10 IL1R1
2 immune system MP:0005387 9.93 BCOR CSF1 CSF3 CTLA4 IL10 IL1R1
3 integument MP:0010771 9.7 CSF1 CSF3 CTLA4 IL10 IL1R1 IL1RN
4 respiratory system MP:0005388 9.28 CSF1 CTLA4 IL10 IL1R1 IL6 MB
Sources

Drugs & Therapeutics for Bone Sarcoma

About this section

Drugs for Bone Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
2
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
4 Antibiotics, Antitubercular Phase 3
5 Anti-Bacterial Agents Phase 3
6 Antifungal Agents Phase 3
7
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166 2942
8
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
9
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
10
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
11
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
12
Sunitinib Approved, Investigational Phase 1, Phase 2 341031-54-7, 557795-19-4 5329102
13
nivolumab Approved Phase 1, Phase 2 946414-94-4
14
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
15
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
16
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
17
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
18
leucovorin Approved Phase 2 58-05-9 6006
19
Gemcitabine Approved Phase 2 95058-81-4 60750
20
Ifosfamide Approved Phase 2 3778-73-2 3690
21
Lenograstim Approved, Investigational Phase 2 135968-09-1
22
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
23
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
26 Exatecan Investigational Phase 2 171335-80-1
27 Tubulin Modulators Phase 2
28
Apatinib Phase 2 811803-05-1
29 Ferrosoferric Oxide Phase 2
30 Parenteral Nutrition Solutions Phase 2
31 Imatinib Mesylate Phase 2 220127-57-1 123596
32 Analgesics, Non-Narcotic Phase 2
33 Anti-HIV Agents Phase 2
34 Interleukin-2 Phase 2
35 Analgesics Phase 2
36 Anti-Retroviral Agents Phase 2
37 Protein Kinase Inhibitors Phase 1, Phase 2
38 Pharmaceutical Solutions Phase 1, Phase 2
39 Angiogenesis Inhibitors Phase 1, Phase 2
40 Antineoplastic Agents, Immunological Phase 1, Phase 2
41 Antirheumatic Agents Phase 2
42 Antiviral Agents Phase 2
43 Alkylating Agents Phase 2
44
Liposomal doxorubicin Phase 2 31703
45 Nutrients Phase 2
46 Protective Agents Phase 2
47 Vitamin B Complex Phase 2
48 Micronutrients Phase 2
49 Hematinics Phase 2
50 Folic Acid Antagonists Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas Completed NCT00538239 Phase 3 ridaforolimus;Placebo
2 Phaseâ…¡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional Unknown status NCT00807261 Phase 2 Gemcitabine and Docetaxel
3 A Phase II Trial of Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck: the RASS Study Unknown status NCT03539172 Phase 2 Apatinib Mesylate
4 A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Completed NCT01310816 Phase 2 IPI-926;Placebo Arm
5 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
6 Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma Completed NCT00802880 Phase 2 Dacarbazine
7 Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI Completed NCT01336803 Phase 2 Feraheme
8 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
9 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
10 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Autologous Tumor Infiltrating Lymphocytes LN-145-S1;Cyclophosphamide;Fludarabine
11 Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable Sarcoma Pulmonary Metastases Recruiting NCT03965234 Phase 1, Phase 2 Cisplatin
12 A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas Recruiting NCT02389244 Phase 2 Regorafenib;Placebo
13 Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas Recruiting NCT03277924 Phase 1, Phase 2 Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent];Nivolumab 100 MG/10 ML [Opdivo]
14 Hyperthermia and Radiotherapy in the Treatment for In-field Recurrent and Radiation-induced Soft Tissue and Bone Sarcomas Recruiting NCT04398095 Phase 2
15 Phase I Study of TQB3525, Phosphatidylinositol-3-Kinase α and δ Inhibitors, in Patients With Advanced Bone Sarcomas Active, not recruiting NCT04690725 Phase 1, Phase 2 TQB3525
16 A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas Active, not recruiting NCT02357810 Phase 2 Pazopanib Hydrochloride;Oral Topotecan Hydrochloride
17 A Randomized, Placebo-controlled, Double-blinded, Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment Not yet recruiting NCT04698785 Phase 2 Treatment by regorafenib and best supportive care;Treatment by placebo and best supportive care
18 A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma Terminated NCT02022358 Phase 2 Glucarpidase;Methotrexate;Folinic Acid
19 Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas Terminated NCT00544778 Phase 2 dexrazoxane hydrochloride;doxorubicin hydrochloride;ifosfamide;irinotecan hydrochloride
20 A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults Terminated NCT03468075 Phase 2 Ascorbate;Gemcitabine
21 Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities Withdrawn NCT01174537 Phase 1, Phase 2
22 An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma Completed NCT01896505 Phase 1 KCP-330
23 In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas Recruiting NCT02811523 Phase 1 Doxorubicin
24 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma Recruiting NCT03462316 Phase 1
25 A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine Active, not recruiting NCT02959164 Phase 1 Decitabine;Gemcitabine
26 A Phase I/II Open-label Study of Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (CIT) in Subjects With Advanced Soft Tissue and Bone Sarcomas Receiving Gemcitabine and Docetaxel Chemotherapy Terminated NCT01491594 Phase 1 Eltrombopag
27 DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study Completed NCT00525057 Dalteparin
28 A European Treatment Protocol for Bone-sarcoma in Patients Older Than 40 Years Completed NCT02986503 Doxorubicin+cisplatin+ifosfamide;Doxorubicin+cisplatin+ifosfamide+methotrexate
29 Cytogenetic and Molecular Genetic Studies in Bone Sarcomas Completed NCT00579930
30 Observational - Tissue Factor Expression in Bone Sarcomas Completed NCT01807052
31 Assessment of Healing and Function After Surgical Reconstruction for Osseous Sarcomas Recruiting NCT03442465
32 A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas Recruiting NCT04055220 Treatment by Regorafenib;Treatment by Placebo
33 A Pilot Study of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults Recruiting NCT04634227 Early Phase 1 Ascorbate
34 Evaluation of Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma Not yet recruiting NCT04735289

Search NIH Clinical Center for Bone Sarcoma

Sources

Genetic Tests for Bone Sarcoma

About this section
Sources

Anatomical Context for Bone Sarcoma

About this section

MalaCards organs/tissues related to Bone Sarcoma:

40
Bone, Breast, Brain, Bone Marrow, Lymph Node, Thyroid, T Cells
Sources

Publications for Bone Sarcoma

About this section

Articles related to Bone Sarcoma:

(show top 50) (show all 873)
# Title Authors PMID Year
1
Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma. 61
33510813 2021
2
Two Cases of Polyethylene Granuloma After Distal Femoral Endoprosthesis With All-Polyethylene Tibia. 61
33553544 2021
3
Unrecognized Chondrosarcoma as a Cause of Total Hip Arthroplasty Failure. 61
33521202 2021
4
Primary bone sarcomas in KSA: A Saudi tumor registry review. 61
33603635 2021
5
Homogenous and Heterogenous Prognostic Factors for Patients with Bone Sarcoma. 61
33305494 2021
6
Primary chest wall sarcoma; a single institution experience of 3 years. 61
33524850 2021
7
Risk factors of regional lymph node (RLN) metastasis among patients with bone sarcoma and survival of patients with RLN-positive bone sarcoma. 61
33553341 2021
8
The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study. 61
33516150 2021
9
Future Directions in the Treatment of Osteosarcoma. 61
33467756 2021
10
Computer Navigation and 3D Printing in the Surgical Management of Bone Sarcoma. 61
33498287 2021
11
Long-term outcomes of non-invasive expandable endoprostheses for primary malignant tumors around the knee in skeletally-immature patients. 61
33417027 2021
12
Has the Volume and Variability of Procedures Reported by Fellows in ACGME-accredited Musculoskeletal Oncology Fellowship Programs Changed Over Time? 61
32732738 2021
13
Sarcoma classification by DNA methylation profiling. 61
33479225 2021
14
Preoperative 3D reconstruction images for paediatric tumours: Advantages and drawbacks. 61
32827349 2021
15
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS). 61
33482247 2021
16
Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research. 61
33452711 2021
17
What sports activity levels are achieved in long-term survivors with modular endoprosthetic humerus reconstruction following primary bone sarcoma resection? 61
33296025 2021
18
Return to Work and Quality of Life in Disease-Free Adult Patients with Soft-Tissue and Bone Sarcoma of the Extremity 61
33406937 2021
19
Medical Care and Survival of Soft-Tissue and Bone Sarcoma Patients: Results and Methodological Aspects of a German Subnational Cohort Study Based on Administrative Healthcare Data. 61
33378758 2020
20
What are the predictors of emergency department utilization and readmission following extremity bone sarcoma resection? 61
32794224 2020
21
CORR Insights®: How Can We Differentiate Local Recurrence From Heterotopic Ossification After Resection and Implantation of an Oncologic Knee Prosthesis in Patients with a Bone Sarcoma? 61
33337603 2020
22
Role of immunotherapy in Ewing sarcoma. 61
33293354 2020
23
Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial. 61
32950930 2020
24
Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis. 61
33088699 2020
25
An association between successful engraftment of osteosarcoma patient-derived xenografts and clinicopathological findings. 61
32964941 2020
26
Co-expression of Epstein-Barr virus-encoded RNA1 and viral latent membrane protein 1 in osteosarcoma: A novel insight of predictive markers. 61
33234011 2020
27
Composite sarcoma of bone with focal rhabdomyosarcoma and lymph node metastasis in an adolescent. 61
32860659 2020
28
KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics. 61
33176814 2020
29
Is Skeletal Imaging Essential in the Staging Workup for Conventional Chondrosarcoma? 61
32567825 2020
30
Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis. 61
33212978 2020
31
Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis - a systematic literature review. 61
33312707 2020
32
GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β. 61
33203838 2020
33
The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa). 61
33266287 2020
34
Prevalence and prognostic impact of comorbidities and peripheral blood indices in sarcomas. 61
33214228 2020
35
Unravelling the heterogeneity of soft tissue and bone sarcoma patients' health-related quality of life: a systematic literature review with focus on tumour location. 61
33082266 2020
36
Bone sarcoma surgery in times of COVID-19 pandemic lockdown-early experience from a tertiary centre in India. 61
32662084 2020
37
Rare cancers of unknown etiology: lessons learned from a European multi-center case-control study. 61
32681390 2020
38
Feasibility and Value of Establishing a Community-Based Virtual Multidisciplinary Sarcoma Case Conference. 61
33049178 2020
39
Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. 61
32873870 2020
40
Plastic lengthening amputation with vascularized bone grafts in children with bone sarcoma: a preliminary report. 61
32933524 2020
41
Complication rate, functional outcomes, and risk factors associated with carbon ion radiotherapy for patients with unresectable pelvic bone sarcoma. 61
32658315 2020
42
Use of hamstring autograft to reconstruct the patellar tendon after endoprosthetic replacement of the proximal tibia for bone sarcomas. 61
31356507 2020
43
Surgical Management of Bone Sarcomas with an Inappropriate Biopsy Site: A Case Series and Review of Literature. 61
33431367 2020
44
Organization of Bone Sarcoma Care: A Cross-Sectional European Study. 61
32588548 2020
45
Associations of Socioeconomic Status, Public vs Private Insurance, and Race/Ethnicity With Metastatic Sarcoma at Diagnosis. 61
32766799 2020
46
Cumulative Burden of Chronic Health Conditions in Adult Survivors of Osteosarcoma and Ewing Sarcoma: A Report from the St. Jude Lifetime Cohort Study. 61
32499311 2020
47
Availability and Readability of Online Patient Information on Osteosarcoma: Assessment of Pediatric Hospital and National Cancer Institute-Designated Cancer Center (NCIDCC) Osteosarcoma Web Pages. 61
32984746 2020
48
Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data. 61
32631311 2020
49
Differentiation of soft tissue and bone sarcomas from benign lesions utilizing 18F-FDG PET/CT-derived parameters. 61
32711449 2020
50
A novel next generation sequencing approach to improve sarcoma diagnosis. 61
32047232 2020
Sources

Variations for Bone Sarcoma

About this section

Cosmic variations for Bone Sarcoma:

9 (show all 49)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM106056882 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
2 COSM111763021 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
3 COSM144313682 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
4 COSM105659131 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
5 COSM93187807 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
6 COSM143375075 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
7 COSM105624912 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
8 COSM122766413 TP53 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 3
9 COSM145021980 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
10 COSM93215390 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
11 COSM143182864 TP53 soft tissue,upper leg,sarcoma,NS c.22C>T p.Q8* 17:7675113-7675113 3
12 COSM144334467 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
13 COSM143972614 TP53 soft tissue,upper leg,sarcoma,NS c.22C>T p.Q8* 17:7675113-7675113 3
14 COSM87902864 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
15 COSM112257156 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
16 COSM142564162 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
17 COSM144655779 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
18 COSM142840367 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
19 COSM122737959 TP53 soft tissue,upper leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 3
20 COSM144111084 TP53 soft tissue,upper leg,sarcoma,NS c.22C>T p.Q8* 17:7675113-7675113 3
21 COSM121881087 TP53 soft tissue,upper leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 3
22 COSM142860117 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
23 COSM144089819 TP53 soft tissue,upper leg,sarcoma,NS c.164A>G p.H55R 17:7674890-7674890 3
24 COSM144682712 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
25 COSM143159971 TP53 soft tissue,upper leg,sarcoma,NS c.164A>G p.H55R 17:7674890-7674890 3
26 COSM122275322 TP53 soft tissue,upper leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 3
27 COSM144041526 TP53 soft tissue,upper leg,sarcoma,NS c.466C>T p.Q156* 17:7675113-7675113 3
28 COSM142592590 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
29 COSM106084061 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
30 COSM112284809 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
31 COSM143401670 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
32 COSM122302302 TP53 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 3
33 COSM143947426 TP53 soft tissue,upper leg,sarcoma,NS c.164A>G p.H55R 17:7674890-7674890 3
34 COSM144017515 TP53 soft tissue,upper leg,sarcoma,NS c.608A>G p.H203R 17:7674890-7674890 3
35 COSM121910283 TP53 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 3
36 COSM111790424 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
37 COSM145045823 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
38 COSM87935416 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
39 COSM92479334 SH2B3 soft tissue,upper leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 3
40 COSM135372634 NUP93 soft tissue,upper leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 3
41 COSM88525472 NUP93 soft tissue,upper leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 3
42 COSM95516578 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
43 COSM95520543 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
44 COSM95523461 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
45 COSM95526780 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
46 COSM87494413 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 3
47 COSM98577250 ANKRD11 soft tissue,upper leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 3
48 COSM87618826 ANKRD11 soft tissue,upper leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 3
49 COSM147901996 ANKRD11 soft tissue,upper leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 3
Sources

Expression for Bone Sarcoma

About this section
Search GEO for disease gene expression data for Bone Sarcoma.
Sources

Pathways for Bone Sarcoma

About this section

Pathways related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.97 TNFRSF1A SRC SERPINA3 IL6 IL1RN IL1R1
2
PEDF Induced Signaling 63
Show member pathways
 13.57 TNFRSF1A SRC IL6 IL1RN IL1R1 IL10
3
Akt Signaling 63
Show member pathways
 13.26 TNFRSF1A SRC IL6 IL1R1 IL10 CXCL8
4
PAK Pathway 63
Show member pathways
 13.13 TNFRSF1A SRC IL6 IL1R1 IL10 CXCL8
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.02 TNFRSF1A SRC IL6 IL1RN IL1R1 IL10
6
Human cytomegalovirus infection 36
Show member pathways
 12.8 TNFRSF1A SRC IL6 IL1R1 CXCL8 CCNB3
7
Salmonella infection (KEGG) 36
Show member pathways
 12.66 TNFRSF1A SRC IL6 IL1R1 CXCL8
8
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.62 SRC IL6 IL1RN IL1R1 CXCL8
9
JAK-STAT signaling pathway 36
Show member pathways
 12.34 SRC IL6 IL10 CSF3
10
Shigellosis 36
12.32 TNFRSF1A SRC IL1R1 CXCL8
11
Tuberculosis 36
12.12 TNFRSF1A SRC IL6 IL10
12
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.06 IL6 IL1RN IL10 CXCL8
13
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.05 TNFRSF1A IL6 IL10 CXCL8 CSF1
14
Yersinia infection 36
11.93 SRC IL6 IL10 CXCL8
15
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.84 IL6 IL10 CSF3 CSF1
16
Amoebiasis 36
11.74 IL6 IL1R1 IL10 CXCL8
17
Hematopoietic cell lineage 36
11.7 IL6 IL1R1 CSF3 CSF1
18
Pertussis 36
11.68 IL6 IL10 CXCL8
19
Dendritic Cells Developmental Lineage Pathway 64
11.67 IL6 IL10 CSF1
20
Rheumatoid arthritis 36
11.64 IL6 CXCL8 CTLA4 CSF1
21
IgA-Producing B Cells in the Intestine 64
11.61 IL6 IL10 CTLA4
22
LPA receptor mediated events 1
11.59 SRC IL6 CXCL8
23
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.57 TNFRSF1A IL6 CXCL8
24
Lung fibrosis 1
11.57 IL6 CXCL8 CSF3
25
Hematopoietic Stem Cell Differentiation 1
11.42 IL6 CSF3 CSF1
26
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.38 SRC IL6 CXCL8
27
Malaria 36
11.16 IL6 IL10 CXCL8 CSF3
28
Interleukin-10 signaling 65
10.92 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8
29
Cytokines and Inflammatory Response 1
10.72 IL6 IL10 CSF3 CSF1
Sources

GO Terms for Bone Sarcoma

About this section

Cellular components related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNFRSF1A SERPINA3 IL6 IL1RN IL1R1 IL10
2 extracellular space GO:0005615 9.32 TNFRSF1A SERPINA3 MIR199A1 MIR100 IL6 IL1RN

Biological processes related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.02 TNFRSF1A SRC IL6 IL1RN IL1R1 IL10
2 positive regulation of gene expression GO:0010628 9.85 SRC KDM4C IL6 CXCL8 CSF1
3 immune response GO:0006955 9.7 IL6 IL1RN IL1R1 IL10 CXCL8 CTLA4
4 cellular response to lipopolysaccharide GO:0071222 9.65 SRC IL6 IL10 CXCL8 CSF3
5 response to glucocorticoid GO:0051384 9.61 IL6 IL1RN IL10
6 branching involved in mammary gland duct morphogenesis GO:0060444 9.51 SRC CSF1
7 acute-phase response GO:0006953 9.5 SERPINA3 IL6 IL1RN
8 inflammatory response GO:0006954 9.5 TNFRSF1A SERPINA3 IL6 IL1RN IL1R1 CXCL8
9 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.49 IL1RN IL10
10 response to molecule of bacterial origin GO:0002237 9.48 IL10 CXCL8
11 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.4 IL6 IL1RN
12 cytokine-mediated signaling pathway GO:0019221 9.23 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8

Molecular functions related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL6 IL10 CSF3 CSF1
2 cytokine activity GO:0005125 9.1 IL6 IL1RN IL10 CXCL8 CSF3 CSF1
Sources

Sources for Bone Sarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....